Global Longitudinal Assessment of Treatment Outcomes in Recurrent/Metastatic Nasopharyngeal Carcinoma: GLANCE‑NPC Study

Cancer research · Nasopharyngeal carcinoma

Patients with recurrent/mets nasopharyngeal carcinoma that have distant metastases have a poor prognosis, highlighting the need for more effective therapies.

Aim: Given a lack of standard of care treatment for R/M NPC, we assessed treatment patterns and overall survival in the real‑world setting. Patients & Methods: A retrospective chart review was conducted in patients who initiated first‑line systemic therapy in Taiwan and South Korea between January 2012–June 2013 with follow‑up through December 2015. Results: Among 154 R/M NPC patients, all patients in Taiwan (n=104) had distant metastases, whereas in South Korea (n=50) 42% had distant metastases. Patients with distant metastases generally received systemic therapy only (71%) for whom median overall survival was 23 months (95% CI: 18‑32). Conclusion: Prognosis in R/M NPC with distant metastases remains poor, underscoring the need for more efficacious treatments.

Our findings demonstrate that R/M NPC patients with distant metastases have a poor prognosis, underscoring the urgent need for more effective treatments to prolong survival.

Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.

Original source

Related signals